{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:58:30Z","timestamp":1792087110998,"version":"4.4.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"Importance<\/jats:title>Current approaches to classify the hepatotoxic potential of medications are based on cumulative case reports of acute liver injury (ALI), which do not consider the size of the exposed population. There is little evidence from real-world data (data relating to patient health status and\/or the delivery of health care routinely collected from sources outside of a research setting) on incidence rates of severe ALI after initiation of medications, accounting for duration of exposure.<\/jats:p><\/jats:sec>Objective<\/jats:title>To identify the most potentially hepatotoxic medications based on real-world incidence rates of severe ALI and to examine how these rates compare with categorization based on case reports.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This series of cohort studies obtained data from the US Department of Veterans Affairs on persons without preexisting liver or biliary disease who initiated a suspected hepatotoxic medication in the outpatient setting between October 1, 2000, and September 30, 2021. Data were analyzed from June 2020 to November 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Outpatient initiation of any one of 194 medications with 4 or more published reports of hepatotoxicity.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Hospitalization for severe ALI, defined by either inpatient: (1) alanine aminotransferase level greater than 120 U\/L plus total bilirubin level greater than 2.0 mg\/dL or (2) international normalized ratio of 1.5 or higher plus total bilirubin level greater than 2.0 mg\/dL recorded within the first 2 days of admission. Acute or chronic liver or biliary disease diagnosis recorded during follow-up or as a discharge diagnosis of a hospitalization for severe ALI resulted in censoring. This study calculated age- and sex-adjusted incidence rates of severe ALI and compared observed rates with hepatotoxicity categories based on cumulative published case reports.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 7 899 888 patients across 194 medication cohorts (mean [SD] age, 64.4 [16.4] years, 7 305 558 males [92.5%], 4 354 136 individuals [55.1%] had polypharmacy). Incidence rates of severe ALI ranged from 0 events per 10\u202f000 person-years (candesartan, minocycline) to 86.4 events per 10\u202f000 person-years (stavudine). Seven medications (stavudine, erlotinib, lenalidomide or thalidomide, chlorpromazine, metronidazole, prochlorperazine, and isoniazid) exhibited rates of 10.0 or more events per 10\u202f000 person-years, and 10 (moxifloxacin, azathioprine, levofloxacin, clarithromycin, ketoconazole, fluconazole, captopril, amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, and ciprofloxacin) had rates between 5.0 and 9.9 events per 10\u202f000 person-years. Of these 17 medications with the highest observed rates of severe ALI, 11 (64%) were not included in the highest hepatotoxicity category when based on case reports.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, incidence rates of severe ALI using real-world data identified the most potentially hepatotoxic medications and can serve as a tool to investigate hepatotoxicity safety signals obtained from case reports. Case report counts did not accurately reflect the observed rates of severe ALI after medication initiation.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2024.1836","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T15:02:35Z","timestamp":1719241355000},"page":"943","source":"Crossref","is-referenced-by-count":42,"title":["Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data"],"prefix":"10.1001","volume":"184","author":[{"given":"Jessie","family":"Torgersen","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa K.","family":"Mezochow","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Newcomb","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M.","family":"Carbonari","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Rentsch","sequence":"additional","affiliation":[{"name":"Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom"},{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley S.","family":"Park","sequence":"additional","affiliation":[{"name":"Center for Population Health Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet P.","family":"Tate","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Br\u00e4u","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York"},{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debika","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mezzacappa","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Njei","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Rutgers University School of Public Health, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar H.","family":"Taddei","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Justice","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven"},{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Division of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Vincent","family":"Lo Re","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ioi240034r1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"issue":"1","key":"ioi240034r2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jhep.2013.02.010","article-title":"Lessons from look-back in acute liver failure? a single centre experience of 3300 patients.","volume":"59","author":"Bernal","year":"2013","journal-title":"J Hepatol"},{"issue":"11","key":"ioi240034r3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.7326\/M15-2211","article-title":"Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study.","volume":"164","author":"Reuben","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3-4","key":"ioi240034r4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drudis.2008.11.009","article-title":"The future of drug safety testing: expanding the view and narrowing the focus.","volume":"14","author":"Stevens","year":"2009","journal-title":"Drug Discov Today"},{"issue":"2","key":"ioi240034r6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports.","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"ioi240034r7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.","volume":"51","author":"Rockey","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"ioi240034r8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/liv.12540","article-title":"Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN).","volume":"35","author":"Hayashi","year":"2015","journal-title":"Liver Int"},{"issue":"8","key":"ioi240034r10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"ioi240034r11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/apt.12923","article-title":"Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.","volume":"40","author":"Husain","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"ioi240034r12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury.","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"ioi240034r13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/pds.3470","article-title":"Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration\u2019s Mini-Sentinel Distributed Database.","volume":"22","author":"Lo Re","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"ioi240034r14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s law: predicting serious hepatotoxicity.","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"ioi240034r15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"ioi240034r16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease.","volume":"42","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"ioi240034r17","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1016\/S2666-7568(21)00206-3","article-title":"Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study.","volume":"2","author":"Justice","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"ioi240034r18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s002280050329","article-title":"Methods for estimating the occurrence of polypharmacy by means of a prescription database.","volume":"53","author":"Bjerrum","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"ioi240034r19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0895-4356(02)00411-0","article-title":"Use of medications and polypharmacy are increasing among the elderly.","volume":"55","author":"Linjakumpu","year":"2002","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"ioi240034r20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/apt.14952","article-title":"Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease\u2014a physiopathological and clinical integrated view.","volume":"48","author":"Bessone","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ioi240034r21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12913-015-1069-8","article-title":"Dual use of VA and non-VA hospitals by veterans with multiple hospitalizations.","volume":"15","author":"West","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"ioi240034r22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjmed.2015.10.029","article-title":"Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status.","volume":"129","author":"Lo Re","year":"2016","journal-title":"Am J Med"},{"issue":"2","key":"ioi240034r23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx012","article-title":"Risk of acute liver injury with antiretroviral therapy by viral hepatitis status.","volume":"4","author":"Gowda","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"ioi240034r5","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Livertox: clinical and research information on drug-induced liver injury. Updated May 13, 2024. Accessed November 16, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/"},{"key":"ioi240034r9","unstructured":"US Department of Veterans Affairs. Corporate data warehouse. Accessed October 28, 2022. https:\/\/www.hsrd.research.va.gov\/for_researchers\/cdw.cfm"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2820267\/jamainternal_torgersen_2024_oi_240034_1728683827.45798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:01:36Z","timestamp":1728918096000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2820267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2024.1836","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}